vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and CPI AEROSTRUCTURES INC (CVU). Click either name above to swap in a different company.
CPI AEROSTRUCTURES INC is the larger business by last-quarter revenue ($19.4M vs $18.7M, roughly 1.0× CytomX Therapeutics, Inc.). CPI AEROSTRUCTURES INC runs the higher net margin — 3.6% vs -0.8%, a 4.4% gap on every dollar of revenue. On growth, CPI AEROSTRUCTURES INC posted the faster year-over-year revenue change (-10.8% vs -25.7%). CPI AEROSTRUCTURES INC produced more free cash flow last quarter ($-2.1M vs $-15.8M). Over the past eight quarters, CPI AEROSTRUCTURES INC's revenue compounded faster (0.9% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
CPI Aerostructures Inc., known as CPI Aero, is a contract aircraft component manufacturer based in Edgewood, New York.
CTMX vs CVU — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $19.4M |
| Net Profit | $-154.0K | $691.8K |
| Gross Margin | — | 20.3% |
| Operating Margin | -6.9% | 6.4% |
| Net Margin | -0.8% | 3.6% |
| Revenue YoY | -25.7% | -10.8% |
| Net Profit YoY | 97.6% | -28.8% |
| EPS (diluted) | — | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $19.4M | ||
| Q3 25 | — | $19.3M | ||
| Q2 25 | $18.7M | $15.2M | ||
| Q1 25 | $50.9M | $15.4M | ||
| Q4 24 | $38.1M | $21.8M | ||
| Q3 24 | $33.4M | $19.4M | ||
| Q2 24 | $25.1M | $20.8M | ||
| Q1 24 | $41.5M | $19.1M |
| Q4 25 | — | $691.8K | ||
| Q3 25 | — | $1.1M | ||
| Q2 25 | $-154.0K | $-1.3M | ||
| Q1 25 | $23.5M | $-1.3M | ||
| Q4 24 | $18.9M | $971.5K | ||
| Q3 24 | $5.7M | $749.7K | ||
| Q2 24 | $-6.5M | $1.4M | ||
| Q1 24 | $13.8M | $168.2K |
| Q4 25 | — | 20.3% | ||
| Q3 25 | — | 22.3% | ||
| Q2 25 | — | 4.4% | ||
| Q1 25 | — | 10.7% | ||
| Q4 24 | — | 20.0% | ||
| Q3 24 | — | 21.7% | ||
| Q2 24 | — | 24.6% | ||
| Q1 24 | — | 18.6% |
| Q4 25 | — | 6.4% | ||
| Q3 25 | — | 9.1% | ||
| Q2 25 | -6.9% | -13.1% | ||
| Q1 25 | 44.4% | -7.7% | ||
| Q4 24 | 46.4% | 9.5% | ||
| Q3 24 | 12.3% | 7.6% | ||
| Q2 24 | -33.7% | 11.2% | ||
| Q1 24 | 28.1% | 4.4% |
| Q4 25 | — | 3.6% | ||
| Q3 25 | — | 5.8% | ||
| Q2 25 | -0.8% | -8.7% | ||
| Q1 25 | 46.2% | -8.6% | ||
| Q4 24 | 49.6% | 4.5% | ||
| Q3 24 | 17.2% | 3.9% | ||
| Q2 24 | -26.0% | 6.8% | ||
| Q1 24 | 33.3% | 0.9% |
| Q4 25 | — | $0.04 | ||
| Q3 25 | — | $0.09 | ||
| Q2 25 | — | $-0.10 | ||
| Q1 25 | — | $-0.10 | ||
| Q4 24 | — | $0.08 | ||
| Q3 24 | — | $0.06 | ||
| Q2 24 | — | $0.11 | ||
| Q1 24 | — | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | — |
| Total DebtLower is stronger | — | $0 |
| Stockholders' EquityBook value | $119.9M | $25.8M |
| Total Assets | $175.1M | $75.2M |
| Debt / EquityLower = less leverage | — | 0.00× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $49.0M | — | ||
| Q1 25 | $47.6M | — | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $40.6M | — | ||
| Q2 24 | $43.2M | — | ||
| Q1 24 | $36.2M | — |
| Q4 25 | — | $0 | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $26.5K | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $25.8M | ||
| Q3 25 | — | $25.0M | ||
| Q2 25 | $119.9M | $23.8M | ||
| Q1 25 | $25.0M | $24.9M | ||
| Q4 24 | $-456.0K | $25.9M | ||
| Q3 24 | $-23.5M | $24.9M | ||
| Q2 24 | $-31.2M | $24.1M | ||
| Q1 24 | $-31.7M | $22.5M |
| Q4 25 | — | $75.2M | ||
| Q3 25 | — | $74.1M | ||
| Q2 25 | $175.1M | $72.3M | ||
| Q1 25 | $98.5M | $65.4M | ||
| Q4 24 | $120.5M | $68.0M | ||
| Q3 24 | $139.0M | $68.9M | ||
| Q2 24 | $159.2M | $70.2M | ||
| Q1 24 | $184.7M | $70.8M |
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $-2.1M |
| Free Cash FlowOCF − Capex | $-15.8M | $-2.1M |
| FCF MarginFCF / Revenue | -84.6% | -10.8% |
| Capex IntensityCapex / Revenue | 0.1% | 0.0% |
| Cash ConversionOCF / Net Profit | — | -3.03× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $-5.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-2.1M | ||
| Q3 25 | — | $212.1K | ||
| Q2 25 | $-15.8M | $-596.3K | ||
| Q1 25 | $-21.0M | $-2.7M | ||
| Q4 24 | $-19.9M | $4.4M | ||
| Q3 24 | $-20.7M | $715.1K | ||
| Q2 24 | $-19.5M | $-591.7K | ||
| Q1 24 | $-26.0M | $-960.5K |
| Q4 25 | — | $-2.1M | ||
| Q3 25 | — | $211.1K | ||
| Q2 25 | $-15.8M | $-599.8K | ||
| Q1 25 | $-21.2M | $-2.8M | ||
| Q4 24 | $-20.0M | $4.3M | ||
| Q3 24 | $-20.7M | $586.9K | ||
| Q2 24 | $-19.6M | $-746.9K | ||
| Q1 24 | $-26.2M | $-1.0M |
| Q4 25 | — | -10.8% | ||
| Q3 25 | — | 1.1% | ||
| Q2 25 | -84.6% | -4.0% | ||
| Q1 25 | -41.6% | -18.1% | ||
| Q4 24 | -52.5% | 19.9% | ||
| Q3 24 | -62.1% | 3.0% | ||
| Q2 24 | -78.2% | -3.6% | ||
| Q1 24 | -63.1% | -5.3% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | 0.1% | 0.0% | ||
| Q1 25 | 0.2% | 0.4% | ||
| Q4 24 | 0.2% | 0.3% | ||
| Q3 24 | 0.1% | 0.7% | ||
| Q2 24 | 0.4% | 0.7% | ||
| Q1 24 | 0.3% | 0.2% |
| Q4 25 | — | -3.03× | ||
| Q3 25 | — | 0.19× | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | 4.53× | ||
| Q3 24 | -3.61× | 0.95× | ||
| Q2 24 | — | -0.42× | ||
| Q1 24 | -1.89× | -5.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
CVU
| Government Subcontracts | $16.4M | 85% |
| Commercial Contracts | $2.3M | 12% |
| Prime Government Contracts | $725.8K | 4% |
